Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study - Gordon, David; Kelley, Peter; Heinzel, Susanne; Cooper, Peter; Petrovsky, Nikolai (Vaccine, 2014)
Keywords: Adjuvant; Adjuvants, Immunologic - administration & dosage; Adult; adults; Advax; Allergy and Immunology; alum; Antibodies, Viral - blood; Antigens; Applied microbiology; Australia; Biological and medical sciences; CD4-positive T-lymphocytes; CD4-Positive T-Lymphocytes - immunology; cell-mediated immunity; Clinical trial; Clinical trials; Delta inulin; Diabetes; Female; Fundamental and applied biological sciences. Psychology; Hepatitis; Hepatitis B; Hepatitis B - prevention & control; hepatitis B antigens; Hepatitis B Surface Antigens - immunology; Hepatitis B Vaccines - therapeutic use; Hepatitis B virus; HIV; Human; Human immunodeficiency virus; Human viral diseases; Humans; immune response; Immunogenicity; Infections; Infectious diseases; injection site; inulin; Inulin - administration & dosage; Inulin - analogs & derivatives; Liver; Male; Medical sciences; Microbiology; Miscellaneous; New Zealand; pain; Phase 1; Safety; Single-Blind Method; Studies; Vaccine; vaccine adjuvants; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral diseases; Viral hepatitis; Virology; West Nile virus; Young Adult; Australia; New Zealand; Human; Clinical trial; Advax; Vaccine; Adjuvant; Delta inulin; Phase 1; Hepatitis B; Hepatitis B surface antigen; Orthohepadnavirus; Hepatic disease; Infection; Virus; Viral hepatitis B; Immunogenicity; Hepadnaviridae; Viral disease; Immunological adjuvant; Viral hepatitis delta; Inulin; Digestive diseases; Hepatitis B virus; Prebiotic; Polysaccharide